Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-HPV16 E7/Protein E7 Antibody (R4D91)

Catalog #:   RVV08909 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG
Applications: ELISA-cap
Accession: P03129
Overview

Catalog No.

RVV08909

Species reactivity

Human papillomavirus type 16 (HPV16)

Host species

Mouse

Isotype

IgG

Clonality

Monoclonal

Target

E7, Protein E7

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03129

Applications

ELISA-cap

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R4D91

Data Image
References

A Luminescence-Based Method for In Vitro Screening of Immunomodulatory Checkpoints and Therapeutics., PMID:40402459

Immunization with recombinant HPV16-E7d in fusion with Flagellin as a cancer vaccine: Effect of antigen-adjuvant orientation on the immune response pattern., PMID:39939497

Development and evaluation of a novel E7 multi-epitopic vaccine for human papillomavirus type 16: design, expression, purification, and immunological characterization., PMID:39910471

HPV16 mutant E6/E7 construct is protective in mouse model., PMID:39350162

MAL expression downregulation through suppressive H3K27me3 marks at the promoter in HPV16-related cervical cancers is prognostically relevant and manifested by the interplay of novel MAL antisense long noncoding RNA AC103563.8, E7 oncoprotein and EZH2., PMID:38461243

Evaluation of HPV 16 and HPV 18 Oncoprotein Expression as Alternative Diagnostic Tools in Cervical Lesion., PMID:38415538

A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses., PMID:37895145

Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines., PMID:37626903

A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics., PMID:37559730

HPV types 16/18 L1 E6 and E7 proteins seropositivity and cervical cancer risk in HIV-positive and HIV-negative black South African women., PMID:35351184

Immunohistochemical Detection of Human Papillomavirus 16 E7 Oncoprotein in Cervical Lesions., PMID:34729114

Targeting Human Papillomavirus-Associated Cancer by Oncoprotein-Specific Recombinant Antibodies., PMID:34502053

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers., PMID:34432728

Antigen Delivery to DEC205+ Dendritic Cells Induces Immunological Memory and Protective Therapeutic Effects against HPV-Associated Tumors at Different Anatomical Sites., PMID:34345218

Serum HPV16 E7 Oncoprotein Is a Recurrence Marker of Oropharyngeal Squamous Cell Carcinomas., PMID:34282779

Enhancing immunogenicity of HPV16 E7 DNA vaccine by conjugating codon-optimized GM-CSF to HPV16 E7 DNA., PMID:34247810

Investigating the association between serum human papillomavirus type 16 E7 antibodies and risk of head and neck cancer., PMID:33949155

ePCL Electrospun Microfibrous Layers for Immune Assays: Sensitive ELISA for the Detection of Serum Antibodies Against HPV16 E7 Oncoprotein., PMID:33842749

Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model., PMID:33627686

Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors., PMID:33485370

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody., PMID:33468698

Evaluation of HPV16 E7 expression in head and neck carcinoma cell lines and clinical specimens., PMID:33335126

PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model., PMID:33108473

A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)., PMID:32918586

Epitope Mapping and Computational Analysis of Anti-HPV16 E6 and E7 Antibodies in Single-Chain Format for Clinical Development as Antitumor Drugs., PMID:32640530

A preliminary study on the immune responses of HPV16-E7 by combined intranasal immunization with lymphotoxin., PMID:32627150

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine., PMID:32554612

Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18., PMID:32214362

Preparation, Characterization and Diagnostic Valuation of Two Novel Anti-HPV16 E7 Oncoprotein Monoclonal Antibodies., PMID:32204370

Antibodies against human papillomavirus proteins in Barrett's dysplasia and intramucosal esophageal adenocarcinoma., PMID:32170783

A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer., PMID:32151670

Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment., PMID:32111835

CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies., PMID:31964784

FLT3L and granulocyte macrophage colony-stimulating factor enhance the anti-tumor and immune effects of an HPV16 E6/E7 vaccine., PMID:31881013

The Intracellular Delivery Of Anti-HPV16 E7 scFvs Through Engineered Extracellular Vesicles Inhibits The Proliferation Of HPV-Infected Cells., PMID:31806970

TCR sequencing paired with massively parallel 3' RNA-seq reveals clonotypic T cell signatures., PMID:31745340

A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3., PMID:31576684

Prognostic value of posttreatment HPV-specific antibodies in patients with oropharyngeal tumors., PMID:30986340

Post-treatment human papillomavirus antibody kinetics in cervical cancer patients., PMID:30955486

Nanobody against the E7 oncoprotein of human papillomavirus 16., PMID:30849663

Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women., PMID:30755156

Extracellular overproduction of E7 oncoprotein of Iranian human papillomavirus type 16 by genetically engineered Lactococcus lactis., PMID:30678667

Increased Response of Human T-Lymphocytes by Dendritic Cells Pulsed with HPV16E7 and Pleurotus sajor-caju-β-glucan (PBG)., PMID:30593739

Nuclear lactate dehydrogenase A senses ROS to produce α-hydroxybutyrate for HPV-induced cervical tumor growth., PMID:30356100

Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer., PMID:30353680

Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice., PMID:30192395

Small Heat Shock Proteins B1 and B6: Which One is the Most Effective Adjuvant in Therapeutic HPV Vaccine?, PMID:30171788

Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice., PMID:30131378

Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers., PMID:30054333

A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer., PMID:30026865

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-HPV16 E7/Protein E7 Antibody (R4D91) [RVV08909]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only